The latest market report published by Credence Research, Inc. “Global Small Animals Respiratory Diseases Treatment Market – Growth, Share, Opportunities, Pipeline Analysis, Competitive Analysis, and Forecast, 2016 – 2024,” the small animals respiratory diseases treatment market was valued at USD 18,350.2 Mn in 2015, and is expected to reach USD 23,064.0 Mn by 2024, expanding at a CAGR of 2.5% from 2016 to 2024.
Browse the full report Small Animals Respiratory Diseases Treatment Market – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 – 2024 report at http://www.credenceresearch.com/report/small-animal-respiratory-diseases-treatment-market
According to veterinary health experts, symptoms and diseases related with respiratory infection are frequent during the first of year life in small animals. These respiratory infections are usually caused by bacteria and virus transferred through an environmental media. The Banfield Pet Hospital suggested that in the U.S obesity in pets is increasing swiftly these days around 37% of dogs analyzed were overweight and around 90% of cats analyzed were obese. Thus, obesity is one of the prominent causes of respiratory diseases and other chronic disorders in small animals.
The market segmentation of small animal respiratory diseases treatment comprises type of diseases and drug class. According to market experts, allergic pneumonitis, canine influenza, rhinitis and sinusitis and tonsillitis were observed as the most common respiratory diseases observed in small animals. The most common symptoms observed in small animals such as coughing or dyspnoea with common disorders such as brachycephalic syndrome, laryngeal paralysis, tracheal collapse, and feline asthma syndrome According to American Veterinary Medical Foundation, the first recognized U.S. outbreak of H3N2 canine influenza occurred in 2015, starting in Chicago and spreading to other Midwestern states. Since March 2015, outbreaks have occurred in a number of areas throughout the U.S. and thousands of dogs have been confirmed positive for the H3N2 virus. It was observed that prevalence of canine influenza was also observed in cats and the displayed signs of upper respiratory disease including discharge, congestion, malaise, lip smacking and excessive salivation. In 2015, it was observed that anthelmintics, corticosteroids and antibiotics accounted for more than 50% market share of the overall small animal respiratory diseases treatment market. According to market experts, most anthelmintics have wide safety margins, i.e., the dosage that can be given to an animal before adverse effects are induced is much higher than the dosage recommended for use.
North America was observed as the largest market for small animal respiratory diseases treatment market due to factors such as rising air pollution, lack of sanitation related to pets in a few households, increasing urban trend of having dogs and cats as pets and rising awareness associated with the well-being of small animals.
Request Free Sample : http://www.credenceresearch.com/sample-request/58332
Key Market Movements:
- Rising air pollution accompanied with increasing obesity issues in pets
- Lack of sanitization associated with pets and increasing urban trend of having dogs and cats as pets
- There is a noticeable inclination towards pet humanization, especially among young, urban and affluent consumers, and is expected to trade up to mid-priced or premium products
Credence Research is a worldwide industry research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Who we are
Credence Research is a worldwide firm, containing more than 15 research consultants and almost 100 research and information professionals.
Our customers mirror our worldwide nature. Around 45% are in Europe, 30% in the Americas, 13% in Asia Pacific and 12% in the Middle East and Africa.
Our firm is intended to work as one. We are a solitary global research organization united by a solid arrangement of qualities, concentrated on customer effect.
Name: Chris Smith (Global Sales Manager)
Address: 105 N 1st ST #429, SAN JOSE,
CA 95103, United States